Search

Purpose: Broader clinical adoption of breast magnetic resonance imaging (MRI) faces challenges such as limited availability and high procedural costs. Low-field technology has shown promise in addressing these challenges. We report our initial experience using a next-generation scanner for low-field breast MRI at 0.55T., Methods: This initial cases series was part of an institutional review board-approved prospective study using a 0.55T scanner (MAGNETOM Free.Max, Siemens Healthcare, Erlangen/Germany: height < 2 m, weight < 3.2 tons, no quench pipe) equipped with a seven-channel breast coil (Noras, Höchberg/Germany). A multiparametric breast MRI protocol consisting of dynamic T1-weighted, T2-weighted, and diffusion-weighted sequences was optimized for 0.55T. Two radiologists with 12 and 20 years of experience in breast MRI evaluated the examinations., Results: Twelve participants (mean age: 55.3 years, range: 36-78 years) were examined. The image quality was diagnostic in all examinations and not impaired by relevant artifacts. Typical imaging phenotypes were visualized. The scan time for a complete, non-abbreviated breast MRI protocol ranged from 10:30 to 18:40 min., Conclusion: This initial case series suggests that low-field breast MRI is feasible at diagnostic image quality within an acceptable examination time., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: M. Dietzel: no competing interest, S. Ohlmeyer: no competing interest, F. Laun: no competing interest, S. Bickelhaupt: no competing interest, R. Heiss and M. Uder: Member of speakers bureau of Siemens Healthineers., (Copyright © 2024. Published by Elsevier B.V.)

Dedicated breast computed tomography (BCT) is an emerging breast imaging modality. The latest development has been the introduction of a spiral breast computed tomography scanner equipped with a photon-counting detector (SBCT). SBCT promises multiple advantages: Unlike conventional mammography, contrast enhanced spectral mammography (CESM: both 2D), and digital breast tomosynthesis (DBT: pseudo 3D), SBCT enables 3D breast imaging without tissue overlap. SBCT achieves high isotropic spatial resolution of breast tissue enabling the assessment of both soft tissue and microcalcifications. Similar to CESM and MRI, SBCT supports contrast-enhanced imaging, enabling the assessment of breast neovascularization. Unlike mammography and its derived methods (CESM, DBT), SBCT does not require compression of the breast. Accordingly, women consistently report significantly increased patient comfort compared to mammography in a previous investigation. Radiation safety is crucial in breast imaging. Studies showed different results in terms of dose, with some staying within the limits of two-view FFDM defined by the ACR and others exceeding the limit by up to 21%. Therefore, a higher radiation dose compared to state-of-the-art mammography and DBT systems has to be acknowledged. SBCT is currently under scientific investigation in multiple trials. Three major indications are currently explored: Whereas our colleagues in Zurich/Switzerland investigate the role of SBCT for opportunistic screening, in our department SBCT is mainly indicated for the work-up of equivocal lesions, and for preoperative staging. In this narrative review, we summarize the concepts of SBCT and potential implications for patient care. We report on our initial clinical experience with the technology and outline future developments of SBCT., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022. Published by Elsevier B.V.)

Purpose: To intra-individually compare patient comfort of spiral breast computed tomography (SBCT) versus digital mammography (DM)., Method: This prospective IRB approved study included 79 patients undergoing both SBCT and DM for the assessment of BI-RADS 4 - 6 lesions. Following SBCT and DM patients answered a standardized questionnaire regarding "Overall patient comfort" and "Pain" on a 5-point Likert Scale. On the same Likert Scale, experienced radiologic technicians rated the workflow of the SBCT regarding patients' "Mobility", ease of patient "Positioning", patients' adherence to the examination ("Compliance") and expected image quality. Visibility of fibroglandular tissue in SBCT was independently rated by two breast radiologists on a 10-point Likert Scale. Subgroups stratified by menopausal status and body mass index (BMI) were analyzed., Results: Patients reported significantly lower pain during SBCT (4.73 ± 0.57) compared to DM (4.09 ± 0.90; P < 0.01). This effect was independent from BMI. However, pain reduction by SBCT was most pronounced in premenopausal (SBCT vs. DM: 4.79 ± 0.50 vs. 3.89 ± 0.99) compared to postmenopausal patients (4.71 ± 0.77 vs. 4.20 ± 0.89). Overall patient comfort in premenopausal patients tended to be higher in SBCT compared to DM (P = 0.08). Radiologic technicians rated the SBCT procedure generally as positive (average: 4.62 ± 0.56). Coverage of fibroglandular tissue in SBCT was generally high (9.82 ± 0.43) and interrater agreement was good (κ = 0.77)., Conclusions: Patients experience less pain during spiral breast computed tomography compared to DM, especially in premenopausal women. Imaging is feasible at a high level of anatomical breast coverage and without problems with the clinical workflow., (Copyright © 2021 Elsevier B.V. All rights reserved.)

Objective: We performed a prospective monocentric study to inter-individually compare the diagnostic accuracy of breast MRI at 1.5 T and 3 T., Methods: During a consecutive period of 12 months all 982 patients receiving breast MRI according to standard indications (problem solving, preoperative staging) were randomized to one 3 T or 1.5 T scanner both equipped with dedicated 16-channel breast coils. Protocols at 1.5 T and 3 T were optimized and in line with international recommendations. Due to restricted time slot availabilities, the randomization-key was defined as 1/10 (3 T/1.5 T). All examinations were read by two experts in breast MRI (>25 and 8 years of experience) who assigned a BI-RADS category per breast. Histopathological verification or long-term MRI follow-up (>24 months) served as standard of reference. Results were analyzed using cross tabulations, standard estimates of diagnostic accuracy, Chi-square test and Mann-Whitney U test (alpha = 5%)., Results: 1961 breasts were included. 1746 (89%) were imaged at 1.5 T and 215 at 3 T (11%). The 1.5 T and 3 T study cohort did not show significant differences regarding patient age (P = 0.71), results of the reference standard (P = 0.09) and indication for MRI (P = 0.53). Overall Sensitivity (94.7%), Specificity (91.4%), Accuracy (91.9%) and Negative Predictive Value (99.0%) were within the range of the literature. Pairwise comparison of Sensitivity (1,5 T/3 T: 94.1/97.9%), Specificity (91.6/%89.3%), Accuracy (92.0%/91.2%) and Negative Predictive Value (98.9%/99.3%) were without significant differences (P = 0.29-0.74)., Conclusion: In this prospective monocentric study, we identified comparably high diagnostic accuracy for both 1.5 T and 3 T breast MRI. Both 1.5 T and 3 T are equally suited for breast imaging., (Copyright © 2019 Elsevier B.V. All rights reserved.)

Rationale and Objectives: To evaluate if contrast enhanced sonography (CES) can help to detect gallbladder inflammation and differentiate between acute and chronic cholecystitis., Materials and Methods: Thirty-three patients with clinical suspicion of acute cholecystitis were examined with CES before cholecystectomy. Thirty patients with no history of gallbladder disease served as control. CES was performed using 2.5 mL SonoVue. A small mechanical index was chosen (0.1). The enhancement pattern of the gallbladder was ranked in a three-point scale: no enhancement, low enhancement and strong enhancement. 28/33 patients underwent surgery. Sonographic findings were compared to histological results., Results: In 16/20 cases with histological proven acute cholecystitis, the gallbladder wall showed a strong enhancement. Low enhancement was found in four patients with acute and in six patients with chronic cholecystitis. The gallbladder wall of two patients with chronic inflammation and all patients (30/30) of the control group showed no enhancement., Conclusion: CES is a feasible tool for detecting gallbladder inflammation. Differentiating between acute and chronic cholecystitis seems to be possible.

Purpose: The accuracy of breast cancer staging involves the estimation of the tumor size for the initial decision-making in the treatment. We investigated the accuracy of tumor size estimation and the association between tumor characteristics and breast density (BD)., Materials and Methods: A total of 434 women with a primary diagnosis of breast cancer were included in this prospective study at a specialist breast unit. Estimated tumor characteristics included tumor size, nodal status, estrogen/progesterone receptor status, Ki-67, HER2/neu, vascular invasion. Radiomorphological data included tumor size as assessed by mammography, breast ultrasonography, and clinical examination, and American College of Radiology (ACR) categories for BD., Results: BD did not have a significant impact on the assessment of tumor size using breast ultrasound (deviation from ACR categories 1-4: 0.55-0.68 cm; P=0.331). The deviation in mammography was significantly different dependent on BD (0.42-0.9 cm; P<0.001). The clinical examination was not affected by BD. Age and tumor size were the only parameters associated with a denser breast in the multivariate analysis. Older women were less likely to have dense breasts (odds ratio 0.157 for women aged >or=70 years), and patients with larger tumors were less likely to have dense breasts (adjusted OR 0.36 for tumors>2 cm)., Conclusion: Breast ultrasonography is more accurate than mammography for assessing tumor size in breasts with a higher BD. The difference in tumor size assessment needs to be taken into consideration in the design of clinical trials and treatment decisions.